Biotech
-
HHS abandons mRNA vaccine research
One vaccine expert called the move, which cancels some $500 million in messenger RNA research contracts, a “giant step backward…
Read More » -
Gates Foundation pledges $2.5B toward women’s health research
The investment, which the foundation says is its largest in women’s health to date, will support research in maternal health,…
Read More » -
Regeneron cancer bispecific rejected again; Allogene discloses trial death
The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts…
Read More » -
Trump redoubles threats in attempt to strongarm drugmakers on prices
The White House set a 60-day deadline for drugmakers to agree on “most favored nation” prices for Medicaid as well…
Read More » -
Vinay Prasad, controversial FDA official, abruptly departs agency
Prasad's exit ends a tumultuous tenure during which he led a reworking of agency guidelines on COVID vaccines and his office…
Read More » -
GenAI and real-world data in pharma: 4 questions to fuel effective insights
To truly unlock the power of RWD, GenAI must go beyond checking a box or staying on trend.
Read More » -
FDA delays approval decision for Bayer menopause therapy
The agency told Bayer it needs additional time to review the non-hormonal drug, called elinzanetant. Regulators in Canada and the…
Read More » -
RFK Jr. adopts CDC panel recommendation to remove thimerosal from flu shots
The action will remove from use the very few flu shots that contain the contested preservative, elevating unproven fears it…
Read More » -
AstraZeneca grows US presence with $50B in spending plans
The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and elsewhere, as…
Read More » -
FDA asks Sarepta to stop shipping Duchenne gene therapy
The company refused the FDA’s request and will continue shipping its therapy, Elevidys, to Duchenne patients who can still walk.…
Read More »